LONG-TERM DEBT - Narrative (Details)			2 Months Ended	3 Months Ended		9 Months Ended
	Mar. 09, 2020 USD ($) $ / shares shares	Jul. 29, 2019 USD ($) lender $ / shares shares	Dec. 31, 2020 USD ($)	Jun. 30, 2024 USD ($)	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($)	Dec. 17, 2019 USD ($)
Debt offering expenses
Incurred expenses related to Credit Agreement and Securities Purchase Agreement		$ 1,100,000				$ 300,000
Interest expense					$ 1,000,000.0	2,900,000
Discount cost					100,000	300,000
Credit Agreement | Level 3
Debt offering expenses
Debt instrument, fair value					36,300,000	36,300,000
Amended And Restated Credit Agreement
Debt instrument information
Long-term debt, gross					35,000,000.0	35,000,000.0	$ 35,000,000.0
Remaining borrowing capacity					15,000,000.0	15,000,000.0
Base interest rate	8.25%
Debt instrument fee as a percent of the aggregate principal amount	1.00%
Minimum aggregate cash balance to maintain after FDA approval	$ 2,500,000
Monthly payment as a percent of the aggregate principal amount beginning July 2023	1.50%
Amended And Restated Credit Agreement | Forecast | Subsequent Event
Debt instrument information
Debt covenant, minimum quarterly revenue compliance			$ 6,000,000.0	$ 97,000,000.0
Amended And Restated Credit Agreement | One-month LIBOR
Debt instrument information
Basis spread on variable rate	2.75%
Amended and Restated Credit Agreement, Trench 1 Loan
Debt instrument information
Debt instrument, face amount		15,000,000
Amended and Restated Credit Agreement, Trench 2 Loan
Debt instrument information
Debt instrument, face amount								$ 20,000,000
Debt offering expenses
Incurred expenses related to Credit Agreement and Securities Purchase Agreement		$ 300,000
Amended and Restated Credit Agreement, Trench 3 Loan
Debt instrument information
Borrowing capacity					$ 15,000,000	$ 15,000,000
Shareholder Lender | Foamix
Warrants issued
Number of ordinary shares that may be purchased by exercise of warrants (in shares) | shares	651,640	1,100,000			1,980,660	1,980,660
Warrant exercise price (in dollars per share) | $ / shares	$ 3.53	$ 2.09			$ 1.1607	$ 1.1607
Shareholder Lender | Credit Agreement
Debt instrument information
Borrowing capacity		$ 50,000,000
Registered offering per securities purchase agreement | Shareholder Lender
Debt instrument information
Number of lenders involved | lender		1
Gross proceeds from issuance of common stock		$ 14,000,000